Drug Database
FI

filgrastim (filgrastim, Nanogen / Ficocyte)

✓ Approved

Nanogen Biopharmaceutical · CSF3R · Recombinant Proteins

What is filgrastim?

filgrastim is a recombinant proteins developed by Nanogen Biopharmaceutical. It is approved for therapeutic indications via injectable (others).

Drug Profile

Brand Namesfilgrastim, Nanogen, Ficocyte
CompanyNanogen Biopharmaceutical
Drug ClassRecombinant Proteins
Molecular TargetCSF3R
RouteInjectable (Others)
StatusApproved
Sources: ClinicalTrials.gov, Nanogen Biopharmaceutical

Mechanism of Action

Molecular Targets

filgrastim acts on 1 molecular target:

CSF3Rcolony stimulating factor 3 receptor (CD114, GCSFR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

filgrastim is developed for 3 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Blood and lymphatic system disordersAnaemia✓ Approved
Blood and lymphatic system disordersNeutropenia✓ Approved
Blood and lymphatic system disordersBone marrow disorder✓ Approved

Related Research Articles

PubMedTransfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie2026-10-09

The Induction Regimen Does Not Affect Stem-Cell Collection in Adult Patients with Ewing Sarcoma.

Scheuble Anne-Marie AM, Heyn Simone S, Bach Enrica E, Pohl Clara C et al.

Ewing sarcoma (ES) is one of the most frequent sarcomas in children and young adults. Dose-intensified induction with vincristine, doxorubicin, cyclophosphamide, ifosfamide and etoposide (VDC/IE) proved to be more efficient than vincristine, ifosfamide, doxorubicin and etoposide (VIDE) and has emerged as a new standard. Here, we analyzed peripheral blood (pB) and stem-cell yields of adult patients after the induction with VDC/IE and compared them with historic control after VIDE induction. Stem-cell collections of 6 adult ES patients (all male) after VDC/IE were analyzed. Stimulation with filgrastim 5 µg/kg bid was applied in all patients. All patients underwent stem-cell collection with a single apheresis without the use of plerixafor. Collections were performed after 2 (n = 2), 3 (n = 1), and 4 (n = 3) courses of induction chemotherapy. Median CD34+ in pB (/µL) was 176.3 compared to 68.3 in the historic cohort (p = 0.26). The median yields of CD34+, CD3+, and CD56+ (106 cells/kg body weight) in the actual and in the historic cohorts did not differ. No difference regarding the collection efficiency nor vitality 24 h after thawing of the cryoconserved products were noticed. Intensification of induction does not seem to affect the feasibility of stem-cell mobilization and the collection or graft composition in adult patients with ES. Confirmation of our findings in larger cohorts is warranted.

PMID 42851975
Read full article →
PubMedResearch in heart yield and translational medicine2026-10-08

Agranulocytosis after High Cumulative Doses of Ceftriaxone in Infective Endocarditis: A Rare but Serious Adverse Reaction.

Baicha Amal A, Aboubakr Khaoula K, Driouach Salma S, Mouine Najat N et al.

Ceftriaxone-induced agranulocytosis is rare but can occur after high cumulative doses (≥60 g) or prolonged therapy.Routine CBC monitoring is essential during long-term ceftriaxone treatment, especially in infective endocarditis.Prompt drug withdrawal, antibiotic switch, and rhG-CSF (filgrastim) administration lead to rapid neutrophil recovery.The Naranjo adverse drug reaction probability scale is a useful tool for causality assessment in antibiotic-induced agranulocytosis. Agranulocytosis is a serious, life-threatening condition characterized by a severe reduction in the number of peripheral neutrophils (<0.5 × 109/L). It is most commonly caused by chemotherapy drugs but can be induced by antibiotics. Ceftriaxone is a widely used and generally safe third generation antibiotic for conditions such as infective endocarditis. Ceftriaxone induced agranulocytosis is an extremely rare adverse reaction. Evidence suggests that this adverse reaction is dose dependent and typically occurs following prolonged courses or high cumulative doses of the antibiotic. Despite improvements in management that reduce the mortality rate to approximately 5%, prompt recognition and treatment remain vital. A 56-year-old man diagnosed with native valve infective endocarditis (Streptococcus mitis) was treated with 2 g/day of intravenous ceftriaxone. In the fifth week of treatment, after receiving a cumulative dose of 60 g, the patient developed severe agranulocytosis, reaching a neutrophil nadir of 0.1 × 109/L. Ceftriaxone was promptly stopped and replaced with teicoplanin, and the patient received filgrastim (recombinant human granulocyte colony stimulating factor [rhG CSF]). The case was classified as a probable adverse drug reaction (Naranjo score, 6). Neutrophil recovery was complete by the seventh day, and the patient successfully underwent double valve replacement surgery. Ceftriaxone induced agranulocytosis, albeit rare, is a potentially fatal complication of prolonged therapy. Regular complete blood count monitoring and prompt management-based on drug withdrawal, appropriate antimicrobial coverage, and rhG CSF administration-are essential for favorable outcomes.

PMID 42847030
Read full article →
PubMedEuropean journal of cancer (Oxford, England : 1990)2026-09-25

Prophylactic use of G-CSFs to reduce neutropenia rates in patients treated with antibody-drug conjugates: A literature review.

Scotté Florian F, Lustberg Maryam M, Aapro Matti M, Ben Abid Fatma F et al.

Although multiple antibody-drug conjugates (ADCs) have demonstrated sufficient efficacy and safety to warrant their approval, many patients require supportive treatment to reduce the severity of ADC-associated toxicities. Clinical guidelines recommend the use of granulocyte colony-stimulating factors (G‑CSFs), such as filgrastim, lenograstim, and long-acting pegfilgrastim, to reduce the duration and severity of chemotherapy-induced neutropenia and the risk of febrile neutropenia (FN). The objective of this literature review was to summarize the available data on the use of G-CSFs in patients treated with ADCs as a strategy to mitigate the risk of severe neutropenia and FN. The identified literature highlight the importance of prophylactic G-CSF use to reduce the occurrence of FN and severe neutropenia in patients treated with ADCs. Although data evaluating the effect of G-CSF use as secondary prophylaxis are limited, available studies highlight the clinical necessity of mitigating neutropenia risk associated with ADCs.

PMID 42790204
Read full article →
PubMedJournal of orthopaedic science : official journal of the Japanese Orthopaedic Association2026-09-17

Efficacy of prophylactic pegfilgrastim compared with therapeutic filgrastim for preventing febrile neutropenia during chemotherapy for musculoskeletal tumors: A single-center retrospective study.

Tanaka Takaaki T, Nakajima Hideaki H, Imura Yoshinori Y, Wakamatsu Toru T et al.

Febrile neutropenia (FN) is a serious adverse event of chemotherapy that can lead to treatment delays, dose reductions, and life-threatening infections. Prophylactic pegylated granulocyte colony-stimulating factor (peg G-CSF; pegfilgrastim) is recommended to reduce FN risk; however, evidence in patients with musculoskeletal tumors receiving diverse chemotherapy regimens remains limited. We retrospectively reviewed 20 patients (104 chemotherapy administrations) with musculoskeletal tumors treated at a single institution between May 2014 and April 2017. Each patient had received at least one cycle of the same regimen with therapeutic filgrastim prior to switching to prophylactic pegfilgrastim, allowing a within-patient comparison. FN incidence and grade 3/4 neutropenia incidence were compared between the filgrastim group (53 administrations) and the pegfilgrastim group (51 administrations) using Fisher's exact test. FN incidence was significantly lower in the pegfilgrastim group (7.8% vs. 26.4%; odds ratio 0.24, 95% CI 0.07-0.78; P = 0.018), as was grade 3/4 neutropenia (60.8% vs. 100%; P < 0.001). In subgroup analyses by regimen, FN was numerically reduced across all regimens but did not reach statistical significance in any individual subgroup, likely owing to limited statistical power. By diagnosis, FN was significantly reduced in osteosarcoma (P = 0.045) but did not reach significance in other diagnostic subgroups. No significant differences were observed in chemotherapy dose intensity, number of cycles, or length of hospital stay. Prophylactic pegfilgrastim significantly reduced FN and severe neutropenia compared with therapeutic filgrastim in musculoskeletal tumor chemotherapy, suggesting that it may offer a clinically meaningful benefit in this patient population and warranting further prospective investigation.

PMID 42754481
Read full article →
PubMedClinical kidney journal2026-09-08

Crescentic transformation induced by granulocyte-colony stimulating factor administration-a case report and review of the literature.

Seshadri Hariharan H, Falahat Yassmin Y, Abdelrahim Waseem W, Geng Yimin Y et al.

The use of recombinant human granulocyte-colony stimulating factor (G-CSF) is an uncommon aetiology for acute kidney injury in cancer patients. Several patterns of renal injury due to G-CSF have been discussed in the literature. Here, we present a case of a 48-year-old man with monoclonal gammopathy of renal significance who received filgrastim for planned autologous stem cell transplantation and developed acute kidney injury presenting as crescentic glomerulonephritis. The patient was treated with steroids, plasmapheresis, and cyclophosphamide. He attained complete recovery and proceeded with stem cell transplantation. We conducted an extensive review of the literature on the subject, which revealed that 10 of the 18 biopsy-proven cases of G-CSF-induced renal injury presented as crescentic glomerulonephritis. When G-CSF is administered to patients with an underlying renal pathology (usually autoimmune or monoclonal in aetiology), the migration and degranulation of activated neutrophils in the glomerular microenvironment in large numbers results in glomerular basement membrane rupture and crescent formation. Timely renal biopsy and aggressive initiation of treatment aid in attaining renal recovery and a favourable prognosis in cancer patients.

PMID 42708005
Read full article →
PubMedRecenti progressi in medicina2026-09-03

[Efficacy and safety of sacituzumab govitecan in patients with metastatic HR+/HER2- pleomorphic lobular breast cancer complicated by renal impairment.]

Martinelli Claudia C

The case concerns a 68-year-old female patient with metastatic HR-positive/HER2-negative pleomorphic lobular breast carcinoma and severe chronic renal impairment since diagnosis, previously treated with multiple lines of therapy. At diagnosis in September 2021, the disease was already metastatic, with bone, nodal, and pleural involvement. The patient received endocrine therapy with CDK4/6 inhibitors, chemotherapy, and targeted agents, with subsequent multiorgan progression. The clinical course was further complicated by persistent severe renal impairment requiring urinary diversion procedures prior to sacituzumab govitecan initiation. In November 2025, the patient experienced multiorgan progression and clinical deterioration (ECOG PS 2), including ascites, peripheral edema, dyspnea, and anorexia. Following multidisciplinary evaluation, sacituzumab govitecan was initiated in December 2025 at full dose (10 mg/kg), with primary prophylaxis using filgrastim. During the first cycle, worsening renal function and grade 2 toxicity occurred, leading to omission of day 8 administration. Treatment was subsequently resumed at a reduced dose (7.5 mg/kg), achieving good tolerability, stabilization of renal function, and clinical benefit. At reassessment in March 2026, a partial response was documented. The patient is currently continuing treatment with overall good tolerability. This case highlights the feasibility of a personalized approach with sacituzumab govitecan in frail patients with severe renal impairment and lobular breast cancer, populations underrepresented in clinical trials.

PMID 42684174
Read full article →

+2288 more articles available with a free account

Sign up free to view all articles →

Ask about filgrastim